PTK2 and nasopharyngeal carcinoma: To examine whether CLCA2 silencing induces nasopharyngeal carcinoma motility via FAK/ERK activation, we tested the motility of nasopharyngeal carcinoma cells following inhibition of FAK and the downstream ERK1/2 pathway.